Pair Name | Gambogic Acid, Sunitinib | ||
Phytochemical Name | Gambogic Acid (PubChem CID: 9852185 ) | ||
Anticancer drug Name | Sunitinib (PubChem CID: 5329102 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Gambogic Acid, Sunitinib | |||
Disease Info | [ICD-11: 2C90.0] | Renal cell carcinoma | Investigative | |
Biological Phenomena | Inhibition-->Angiogenesis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
In Vitro Model | 786-O | Renal cell carcinoma | Homo sapiens (Human) | CVCL_1051 |
Caki-1 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_0234 | |
In Vivo Model | Caki-1 cells (2×10⁶) in 100 ul RPMI-1640 and 100 ul of matrigel were used to inject subcutaneously into each mouse (5-week-old male athymic BALB/c nu/nu mice). | |||
Result | Our results show that the joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone and thus may offer a new treatment strategy for renal cell carcinoma. |
No. | Title | Href |
---|---|---|
1 | Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13(12):6463-8. doi: 10.7314/apjcp.2012.13.12.6463. | Click |